KUALA LUMPUR: At 9.43am, Genting Bhd
's stock was down eight sen or 1.53% to RM5.16 a share, trimming the previous session's steep gains that were underpinned by TauRx Pharmaceuticals Ltd's progress in the development of a drug for Alzheimer's disease.
Genting had seen a surge in investor interest as 20.3%-owned TauRx, a global leader in tau-based research, released optimistic data from the Phase 3 clinical trial of an oral drug for Alzheimer's disease called HMTM.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
